Mei Qiu1, Liang-Liang Ding2, Hai-Rong Zhou1. 1. Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China. 2. Department of Cardiology, First Affiliated Hospital of Yangtze University, Jingzhou, China.
Abstract
BACKGROUND: The efficacy of sodium-glucose transporter 2 inhibitors (SGLT2is) on heart failure outcomes is unestablished in various subgroups defined by clinically important factors. We intended to evaluate the effects of six important factors on the efficacy of SGLT2is on heart failure outcomes. METHODS: We included cardiovascular outcome trials (CVOTs) concerning SGLT2is. We assessed the heart failure composite outcome of cardiovascular death (CVD) or hospitalization for heart failure (HHF). Meta-analysis was conducted stratified by the following 6 factors: type of underlying diseases, type of SGLT2is, left ventricular ejection fraction (LVEF) level, New York Heart Association (NYHA) class, region, and race. RESULTS: Ten CVOTs were included. Compared with placebo, SGLT2is reduced heart failure composite outcome by 25% [hazard ratio (HR) 0.75, 95% confidence interval (CI), 0.72-0.78] independent of type of underlying diseases, type of SGLT2is, LVEF level, and region (Psubgroup: 0.673, 0.244, 0.429, and 0.127, respectively). SGLT2is led to greater reduction in the composite outcome in patients with NYHA class II (HR 0.66, 95% CI, 0.59-0.74) than in patients with NYHA class III or IV (HR 0.86, 95% CI, 0.75-0.99; Psubgroup=0.004), and in Black (HR 0.63, 95% CI, 0.49-0.82) and Asian (HR 0.64, 95% CI, 0.53-0.77) patients than in White patients (HR 0.81, 95% CI, 0.76-0.86; Psubgroup=0.016). CONCLUSIONS: SGLT2is reduce heart failure composite outcome by 25% independent of type of underlying diseases, type of SGLT2is, LVEF level, and region. SGLT2is lead to greater reduction in the composite outcome in patients with NYHA class II than in patients with NYHA class III or IV, and in Black and Asian patients than in White patients. KEYWORDS: Sodium-glucose transporter 2 inhibitors (SGLT2is); heart failure; chronic kidney disease (CKD); type 2 diabetes. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: The efficacy of sodium-glucose transporter 2 inhibitors (SGLT2is) on heart failure outcomes is unestablished in various subgroups defined by clinically important factors. We intended to evaluate the effects of six important factors on the efficacy of SGLT2is on heart failure outcomes. METHODS: We included cardiovascular outcome trials (CVOTs) concerning SGLT2is. We assessed the heart failure composite outcome of cardiovascular death (CVD) or hospitalization for heart failure (HHF). Meta-analysis was conducted stratified by the following 6 factors: type of underlying diseases, type of SGLT2is, left ventricular ejection fraction (LVEF) level, New York Heart Association (NYHA) class, region, and race. RESULTS: Ten CVOTs were included. Compared with placebo, SGLT2is reduced heart failure composite outcome by 25% [hazard ratio (HR) 0.75, 95% confidence interval (CI), 0.72-0.78] independent of type of underlying diseases, type of SGLT2is, LVEF level, and region (Psubgroup: 0.673, 0.244, 0.429, and 0.127, respectively). SGLT2is led to greater reduction in the composite outcome in patients with NYHA class II (HR 0.66, 95% CI, 0.59-0.74) than in patients with NYHA class III or IV (HR 0.86, 95% CI, 0.75-0.99; Psubgroup=0.004), and in Black (HR 0.63, 95% CI, 0.49-0.82) and Asian (HR 0.64, 95% CI, 0.53-0.77) patients than in White patients (HR 0.81, 95% CI, 0.76-0.86; Psubgroup=0.016). CONCLUSIONS: SGLT2is reduce heart failure composite outcome by 25% independent of type of underlying diseases, type of SGLT2is, LVEF level, and region. SGLT2is lead to greater reduction in the composite outcome in patients with NYHA class II than in patients with NYHA class III or IV, and in Black and Asian patients than in White patients. KEYWORDS: Sodium-glucose transporter 2 inhibitors (SGLT2is); heart failure; chronic kidney disease (CKD); type 2 diabetes. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine Journal: N Engl J Med Date: 2018-11-10 Impact factor: 91.245
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Husam M Salah; Subhi J Al'Aref; Muhammad Shahzeb Khan; Malek Al-Hawwas; Srikanth Vallurupalli; Jawahar L Mehta; J Paul Mounsey; Stephen J Greene; Darren K McGuire; Renato D Lopes; Marat Fudim Journal: Am Heart J Date: 2020-10-24 Impact factor: 4.749
Authors: Deepak L Bhatt; Michael Szarek; Bertram Pitt; Christopher P Cannon; Lawrence A Leiter; Darren K McGuire; Julia B Lewis; Matthew C Riddle; Silvio E Inzucchi; Mikhail N Kosiborod; David Z I Cherney; Jamie P Dwyer; Benjamin M Scirica; Clifford J Bailey; Rafael Díaz; Kausik K Ray; Jacob A Udell; Renato D Lopes; Pablo Lapuerta; P Gabriel Steg Journal: N Engl J Med Date: 2020-11-16 Impact factor: 91.245
Authors: Deepak L Bhatt; Michael Szarek; P Gabriel Steg; Christopher P Cannon; Lawrence A Leiter; Darren K McGuire; Julia B Lewis; Matthew C Riddle; Adriaan A Voors; Marco Metra; Lars H Lund; Michel Komajda; Jeffrey M Testani; Christopher S Wilcox; Piotr Ponikowski; Renato D Lopes; Subodh Verma; Pablo Lapuerta; Bertram Pitt Journal: N Engl J Med Date: 2020-11-16 Impact factor: 91.245
Authors: Carlos G Santos-Gallego; Ariana P Vargas-Delgado; Juan Antonio Requena-Ibanez; Alvaro Garcia-Ropero; Donna Mancini; Sean Pinney; Frank Macaluso; Samantha Sartori; Merce Roque; Fernando Sabatel-Perez; Anderly Rodriguez-Cordero; M Urooj Zafar; Icilma Fergus; Farah Atallah-Lajam; Johanna P Contreras; Cathleen Varley; Pedro R Moreno; Vivian M Abascal; Anuradha Lala; Ronald Tamler; Javier Sanz; Valentin Fuster; Juan J Badimon Journal: J Am Coll Cardiol Date: 2020-11-13 Impact factor: 24.094
Authors: Faiez Zannad; João Pedro Ferreira; Stuart J Pocock; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Martina Brueckmann; Anne Pernille Ofstad; Egon Pfarr; Waheed Jamal; Milton Packer Journal: Lancet Date: 2020-08-30 Impact factor: 79.321
Authors: Karin Rådholm; Gemma Figtree; Vlado Perkovic; Scott D Solomon; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Terrance D Barrett; Wayne Shaw; Mehul Desai; David R Matthews; Bruce Neal Journal: Circulation Date: 2018-07-31 Impact factor: 29.690
Authors: Pardeep S Jhund; Mark C Petrie; Naveed Sattar; Matthew M Y Lee; Katriona J M Brooksbank; Kirsty Wetherall; Kenneth Mangion; Giles Roditi; Ross T Campbell; Colin Berry; Victor Chong; Liz Coyle; Kieran F Docherty; John G Dreisbach; Catherine Labinjoh; Ninian N Lang; Vera Lennie; Alex McConnachie; Clare L Murphy; Colin J Petrie; John R Petrie; Iain A Speirits; Steven Sourbron; Paul Welsh; Rosemary Woodward; Aleksandra Radjenovic; Patrick B Mark; John J V McMurray Journal: Circulation Date: 2020-11-13 Impact factor: 39.918